Trial Profile
Open-Label Evaluation of the Pharmacokinetic Profile and Safety of Tapentadol Oral Solution for the Treatment of Postsurgical Pain in Children and Adolescents Aged From 6 to Less Than 18 Years.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Tapentadol (Primary)
- Indications Postoperative pain
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 29 Jan 2014 Status changed from suspended to completed as reported by ClinicalTrials.gov record.
- 21 May 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 13 Nov 2012 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.